TAmiRNA presents new microRNA cardiovascular applications at LABMED Forum Düsseldorf

Vienna, Austria: – Innovative biotech company TAmiRNA will present its latest insights on new applications of circulating microRNAs in cardiology at the upcoming LABMED Forum, part of the MEDICA pharma fair in Düsseldorf, Germany.

TAmiRNA CEO Dr. Matthias Hackl will talk about “Development of miRNA for cardiovascular diagnostics” during the session: ‘Cardiology – More safety with myocardial infarction and heart insufficiency’, which will take place on the afternoon of day two of the event (Tuesday, November 14, 14:40 – 15:00).

Cardiovascular applications

“We are looking forward to meeting biotech and pharma companies participating in clinical studies in cardiovascular disease, academic and clinical research groups at the conference,” said Dr. Hackl.

“In my address and in face to face meetings, I will be able to show the huge potential for personalized monitoring of anti-platelet therapy, and the assessment of bleeding-risk due to impaired platelet activation,” Dr. Hackl explained.

Early diagnosis and retrospective analysis

“We can also offer solutions for risk assessment of adverse cardiovascular events and metabolic diseases,” he added.

“Crucially circulating microRNAs are pathway independent, and allow in vivo measurement of platelet function, making retrospective analysis possible, ” said Dr. Hackl.

“We are looking forward to this valuable opportunity to connect with a highly expert and influential audience of cardiologists and scientists participating in clinical studies ad academia and at clinical research groups,” said Dr. Hackl.

About TAmiRNA

Privately owned and headquartered in Vienna, TAmiRNA GmbH is a biotech company specialized in the identification and validation of non-coding RNAs as biomarkers for age-related diseases. The mission of TAmiRNA is to provide clinically useful biomarkers to improve and prolong patient stability, health and quality of life with increasing age.

TAmiRNA specializes in technologies for profiling levels of blood-circulating microRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for early diagnosis and prognosis of disease, or as companion diagnostic tests to support treatment decisions.

TAmiRNA’s pipeline includes developments in osteoporosis, cardiovascular disease, type-2 diabetes, and cancer, which aim to provide ‘microRNA kit’ solutions that enable users to quantify the levels of specific microRNA combinations and platelet function in serum, plasma, urine or other biofluids. The company initially developed kits for bone disease (osteomiR) and cardiovascular disease (thrombomiR).

TAmiRNA also offers contract research services for companies in need of targeted biomarker development. Customers include biopharma companies with drug development programs in human and veterinary medicine, medtech companies and clinical research groups.

More information available at: www.tamirna.com

About MEDICA 2017

The MEDICA World LABMED Forum for Medicine (MEDICA) is one of the world’s largest medical marketplaces and over the course of 40 years has become a firmly established event on the European life sciences trade fair calendar. This trade fair is hosted annually in Düsseldorf, Germany. The 2015 event attracted more than 130,000 delegates from some 120 nations worldwide.

MEDICA 2017 is a four-day event opening November 13 at Düsseldorf Fairgrounds, with its three halls.

In addition to a professional trade fair, the MEDICA Conferences and Forums have become leading knowledge-sharing platforms including the MEDICA Education Conference, the German Hospital Conference, the biennial European Hospital Conference (EHC), the MEDICA Medicine & Sports Conference, the MEDICA Physio Conference and the International Conference on Disaster and Military Medicine (DiMiMED).

More information at: https://www.medica-tradefair.com/